Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06016764 · ClinicalTrials.gov registry record · Phase 1

Use of MRI and cTBS for Catatonia in Autism

A Phase 1 study, sponsored by Vanderbilt University Medical Center.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target

NCT06016764: Completed Phase 1 study, sponsored by Vanderbilt University Medical Center.

NCT06016764 is a Phase 1 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06016764, a Phase 1 study, has completed, sponsored by Vanderbilt University Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target

Study Summary

Despite the significant morbidity and mortality associated with catatonia in autism, no diagnostic research has attempted to identify biomarkers for catatonia. This application will use a participant's own individual brain magnetic resonance image to target the primary motor strip with transcranial magnetic stimulation; to determine if hyper-excitability of the brain directly correlates with symptoms of catatonia and social-emotional impairment in autism. Completion of this project would result in the first study to associate hyper-excitability of the brain with catatonia and core features of autism; findings which are likely to have a significant impact on the health and well-being of autistic individuals.

Primary Outcome

Three batches of 10 MEPs will be recorded before cTBS and used as a baseline measure of motor evoked potentials.

Interventions

  • DEVICE Continuous Theta Burst in Transcranial Magnetic Stimulation

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2023-08-23
Est. Completion 2025-12-01
Phase Phase 1

What the finished NCT06016764 record still lists

NCT06016764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).

The record links to 0 conditions, and to 1 intervention - of which Continuous Theta Burst in Transcranial Magnetic Stimulation is the first listed.

NCT06016764 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06016764 about?

NCT06016764 is a clinical study titled "Use of MRI and cTBS for Catatonia in Autism". Despite the significant morbidity and mortality associated with catatonia in autism, no diagnostic research has attempted to identify biomarkers for catatonia. This application will use a participant's own individual brain magnetic resonance image to target the primary motor strip with transcranial ...

What is the current status of trial NCT06016764?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2023-08-23. Estimated completion is 2025-12-01.

What interventions are being tested in trial NCT06016764?

The interventions under investigation include: Continuous Theta Burst in Transcranial Magnetic Stimulation (DEVICE).

Who is sponsoring clinical trial NCT06016764?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06016764's enrollment target sits among peer trials

26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06016764, the US trial registry maintained by the National Library of Medicine. NCT06016764 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.